Zhang Xuelian, Zhang Bin, Zhang Chenyang, Sun Guibo, Sun Xiaobo
Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China.
Front Pharmacol. 2021 Mar 25;11:601751. doi: 10.3389/fphar.2020.601751. eCollection 2020.
The prevalence of individuals who are overweight or obese is rising rapidly globally. Currently, majority of drugs used to treat obesity are ineffective or are accompanied by obvious side effects; hence, the options are very limited. Therefore, it is necessary to find more effective and safer anti-obesity drugs. It has been proven and that the active ingredient notoginsenosides isolated from traditional Chinese medicine (Burk.) F. H. Chen exhibits anti-obesity effects. Notoginsenosides can treat obesity by reducing lipid synthesis, inhibiting adipogenesis, promoting white adipose tissue browning, increasing energy consumption, and improving insulin sensitivity. Although notoginsenosides are potential drugs for the treatment of obesity, their effects and mechanisms have not been analyzed in depth. In this review, the anti-obesity potential and mechanism of action of notoginsenosides were analyzed; thus laying emphasis on the timely prevention and treatment of obesity.
全球范围内超重或肥胖个体的患病率正在迅速上升。目前，大多数用于治疗肥胖症的药物无效或伴有明显的副作用；因此，选择非常有限。因此，有必要寻找更有效、更安全的抗肥胖药物。已经证明，从中药三七（Burk.）F. H. Chen中分离出的活性成分三七总皂苷具有抗肥胖作用。三七总皂苷可以通过减少脂质合成、抑制脂肪生成、促进白色脂肪组织棕色化、增加能量消耗和改善胰岛素敏感性来治疗肥胖症。虽然三七总皂苷是治疗肥胖症的潜在药物，但其作用和机制尚未得到深入分析。在这篇综述中，分析了三七总皂苷的抗肥胖潜力和作用机制；从而强调了肥胖症的及时预防和治疗。
